Physician profile
Scott Sullivan
NPI 1689100471
$4,705.03
in general payments reported to CMS, 2019-2025
15 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.87 · 2022: $349 · 2023: $401 · 2024: $3,289 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,947 · Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,946.51 |
| Food and Beverage | $1,330.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $3,212.06 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $246.07 | 2021-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $220.92 | 2021-2023 | Acthar |
| Apellis Pharmaceuticals, INC. | $196.74 | 2023-2025 | Syfovre |
| Ocular Therapeutix, INC. | $147.19 | 2025 | Dextenza |
| Abbvie INC. | $136.12 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $135.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $111.51 | 2023 | Cequa |
| Ani Pharmaceuticals, INC. | $106.92 | 2025 | Yutiq, Iluvien |
| Genentech USA, INC. | $58.16 | 2021-2023 | Vabysmo |
| Musculoskeletal Transplant Foundation INC. | $53.58 | 2025 | |
| Coherus Oncology, INC. | $31.71 | 2023 | |
| Alcon Vision LLC | $16.92 | 2022 | |
| Astellas Pharma US INC | $16.42 | 2025 | Izervay |
| Spark Therapeutics, INC. | $15.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.